Pharmosa Biopharm (ROCO:6875) Other Current Liabilities: NT$20.64 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
27 GF Score
Price NT$32.75
GF Value NT$15.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Pharmosa Biopharm Other Current Liabilities?

Pharmosa Biopharm ROCO:6875 +1.55% 27 Other Current Liabilities is NT$20.64 Mil as of Jun. 2026. GuruFocus rates ROCO:6875 with a GF Score™ of 27/100 and a GF Value™ of NT$15.32 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Pharmosa Biopharm's other current liabilities for the quarter that ended in Jun. 2026 was NT$20.64 Mil.

Pharmosa Biopharm's quarterly other current liabilities declined from Dec. 2025 (NT$24.17 Mil) to Mar. 2026 (NT$15.92 Mil) but then increased from Mar. 2026 (NT$15.92 Mil) to Jun. 2026 (NT$20.64 Mil).

Pharmosa Biopharm's annual other current liabilities increased from Dec. 2023 (NT$27.29 Mil) to Dec. 2024 (NT$40.12 Mil) but then declined from Dec. 2024 (NT$40.12 Mil) to Dec. 2025 (NT$24.17 Mil).

Pharmosa Biopharm Other Current Liabilities Related Terms

Pharmosa Biopharm Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Other Current Liabilities Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 8.87 10.53 27.29 40.12 24.17

Pharmosa Biopharm Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.63 25.17 24.17 15.92 20.64
ROCO:6875
27GF Score
Pharmosa Biopharm Inc ROCO:6875
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of NT$20.64 Mil mean?
Pharmosa Biopharm (ROCO:6875) has a Other Current Liabilities of NT$20.64 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharmosa Biopharm.
Is Pharmosa Biopharm's Other Current Liabilities too high?
Pharmosa Biopharm's current Other Current Liabilities is NT$20.64 Mil. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Other Current Liabilities compare to VRTX and REGN?
Pharmosa Biopharm's Other Current Liabilities of NT$20.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharmosa Biopharm. Pharmosa Biopharm's current Other Current Liabilities is NT$20.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$32.75 — trading 113.8% above its estimated fair value. The current Other Current Liabilities is NT$20.64 Mil. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Other Current Liabilities is NT$20.64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued. The current stock price of NT$32.75 is trading 113.8% above its estimated GF Value™ of NT$15.32. GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.

Key valuation signals for ROCO:6875:

  • Other Current Liabilities: NT$20.64 Mil
  • GF Value™: NT$15.32 vs. price of NT$32.75 (113.8% above fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score

Get the complete analysis for ROCO:6875

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.75
Price
NT$15.32
GF Value